

# SAFETY DATA SHEET

Page 1 of 3

#### SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

Product: POINTING MASTIC Part Number: 5130-000

Manufacturer: W. R. MEADOWS OF CANADA Address: 70 Hannant Court

Milton, Ontario Canada L9T 5C1

**Telephone:** (905) 878-4122 In case of emergency, dial (800) 424-9300 (CHEMTREC)

Revision Date: 5/7/2021

Product Use: Polymeric Sealing Compound

#### SECTION 2: HAZARDS IDENTIFICATION/EXPOSURE LIMITS

HMIS		HAZARD STATEMENTS			
Health	1	WARNING!			
Flammability	[2]	Causes skin/eye irritation.			
Reactivity	[0]	Flammable solid. Avoid ignition sources.			
Personal Protection	ii	Harmful if inhaled.			
		Suspected of damaging fertility or unborn child.			
		May cause organ damage.			
		PRECAUTIONARY STATEMENTS:			
		Use only in well-ventilated areas.			
		Avoid breathing vapors and direct contact.			

Store in well-ventilated location.

Wear appropriate personal protective equipment.

Control vapors in confined spaces utilizing mechanical ventilation.

#### **SECTION 3: HAZARDS COMPONENTS**

	CAS	% by	SARA	Vapor Pressure	LEL	
Chemical Name:	<u>Number</u>	<u>Weight</u>	<u>313</u>	(mm Hg@20°C)	(@25°C)	
1. Petroleum Asphalt	8052-42-4	25-30	No	N/E	N/E	
2. Xylene	1330-20-7	20-25	Yes	6.6	1.1	
3. Propylene Carbonate	108-32-7	1-5	No	0.04 hpa	1.7	
4. Ethylbenzene	100-41-4	1-5	Yes	5.4	1	N/E = Not Established

Under the reporting requirements of Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1966 (SARA) and 40 CFR Part 372, chemicals listed on the 313 List (40 CFR Part 373.65) are identified under the heading "SARA 313."

## **SECTION 4: EMERGENCY AND FIRST AID PROCEDURES**

**EYE CONTACT:** Flush eyes with water for fifteen (15) minutes. If symptoms persist, seek medical attention.

**SKIN CONTACT:** Wash affected areas with mild soap and water. Remove contaminated shoes/clothing. If symptoms persist, seek medical attention. Do not use petroleum solvents to remove solids.

**INHALATION:** If respiratory symptoms develop, move affected individual from exposure source and into fresh air. If symptoms persist, seek medical attention.

**INGESTION:** Dilute with liquid unless the victim is unconscious or very drowsy. Do not induce vomiting. If vomiting spontaneously occurs, prevent lung aspiration. Seek immediate medical attention.

MOST IMPORTANT SYMPTOMS/EFFECTS, ACUTE AND CHRONIC: See Section Eleven for Symptoms/Effects.

## **SECTION 5: FIRE AND EXPLOSIVES HAZARDS**

**FLASHPOINT:** Not applicable; classified as a solid per ASTM D4359.

**EXTINGUISHING MEDIA:** Water fog, foam, dry chemical.

CHEMICAL/COMBUSTION HAZARDS: Carbon monoxide, carbon dioxide, oxides/compounds of sulfur/nitrogen, and

incomplete combustion products.

PRECAUTIONS/PERSONAL PROTECTIVE EQUIPMENT: Avoid smoke inhalation. Use appropriate personal protective equipment.

#### **SECTION 6: ACCIDENTAL RELEASE MEASURES**

**SPILL OR LEAK PROCEDURES:** Avoid direct contact. Product is very thick and will not flow freely. Place in marked, sealed containers for disposal.



## SAFETY DATA SHEET

Date of Preparation: 5/7/2021 Page 2 of 3 5130000

#### SECTION 7: HANDLING AND STORAGE

SAFE HANDLING PROCEDURES: Avoid direct contact. For exterior use only. Avoid sources of ignition.

SAFE STORAGE: Keep containers closed when not in use. Keep away from ignition sources.

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

	OSHA				ACGIH			
<b>Chemical Name:</b>	PEL	PEL/CEILING	PEL/STEL	SKIN	TWA	TLV/CEILING	TLV/STEL	<u>SKIN</u>
1. Petroleum Asphalt	5 mg/m <sup>3*</sup>	N/E	N/E	No	5 mg/m <sup>3*</sup>	N/E	N/E	N/E
2. Xylene	100 ppm	N/E	N/E	No	100 ppm	N/E	150 ppm	No
3. Propylene Carbonate	N/E	N/E	N/E	No	N/E	N/E	N/E	No
4. Ethylbenzene	100 ppm	N/E	N/E	No	100 ppm	N/E	125 ppm	No
		N/F: Not Established		*.	Asnhalt Fumes		• •	

**ENGINEERING CONTROLS:** Use with adequate ventilation. Use explosion-proof equipment.

PERSONAL PROTECTIVE EQUIPMENT: Safety glasses, chemical-resistant gloves.

## **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

BOILING POINT: 284 °F VAPOR DENSITY: >1 (air=1) % VOLATILE BY VOLUME: N/E

EVAPORATION RATE: <1 (Ether=1) pH LEVEL: N/E % VOLATILE BY WEIGHT: 21 (approximate) WEIGHT PER GALLON: N/A PRODUCT APPEARANCE: Black Semi-Solid VOC CONTENT: 207 g/L (Method 24)

WEIGHT PER GALLON: N/A PRODUCT APPEARANCE: Black Semi-Solid VOC CONTENT: 207 g/L (Method 24)

ODOR: Mild Organic ODOR THRESHOLD: N/D MELTING/FREEZING POINT: N/D

 FLASH POINT:
 See Section 5
 See Section 5
 UEL/LEL:
 N/D

 VAPOR PRESSURE:
 N/D
 RELATIVE DENSITY:
 N/D
 SOLUBILITY:
 N/D

PARTITION COEFFICENT: N/D AUTOIGNITION TEMPERATURE: N/D DECOMPOSITION TEMPERATURE: N/D

VISCOSITY: N/D N/A: Not Applicable N/D: Not Determined N/E: Not Established

### SECTION 10: STABILITY/REACTIVITY

STABILITY: Stable. HAZARDOUS POLYMERIZATION: Will not occur.

**CONDITIONS AND MATERIALS TO AVOID:** Oxidizing agents, strong acids, and strong alkalies.

HAZARDOUS DECOMPOSITION PRODUCTS: Carbon monoxide, carbon dioxide, oxides/compounds of sulfur/nitrogen and

incomplete combustion products.

### **SECTION 11: TOXICOLOGICAL INFORMATION**

**EYE CONTACT:** Direct contact may cause mild to moderate irritation. Product vapors/mists may also cause irritation.

**SKIN CONTACT:** Direct contact may cause slight skin irritation. Prolonged/repeated contact may result in irritation/dermatitis. **INHALATION:** Exposure may cause irritation of the nose, throat, respiratory tract, and other mucous membranes. Exposure to excessive vapor concentrations may cause signs of transient central nervous system depression (headache, fatigue, drowsiness, dizziness, loss of coordination).

**INGESTION:** May result in irritation of the gastrointestional tract. Ingestion of excessive quantities may result in symptoms of transient central nervous system depression as noted above.

**SIGNS AND SYMPTOMS:** Symptoms of eye irritation include tearing, reddening, and swelling. Symptoms of skin irritation include redness and swelling. Gastrointestinal irritation symptoms include nausea, vomiting, and abdominal discomfort. Symptoms of respiratory irritation include runny nose, sore throat, coughing, chest discomfort, shortness of breath, and reduced lung function. Symptoms of transient central nervous system depression include: headache, fatigue, drowsiness, dizziness, and loss of coordination.

**AGGRAVATED MEDICAL CONDITIONS:** Pre-existing skin, eye, and respiratory disorders may be aggravated by exposure to this product.

**OTHER HEALTH EFFECTS:** Xylene may cause damage to the following organs: blood, kidneys, lungs, liver, mucous membranes, heart, upper respiratory tract, skin, auditory system, central nervous system, eye, lens, and cornea. Ethyl Benzene is considered possibly carcinogenic to humans by IARC (Group 2B) based on laboratory animal studies. Some asphalts may possess weak carcinogenic activity. Repeated direct skin contact should be avoided. Occasional contact with asphalt is not expected to have serious health effects as long as good personal hygiene measures are followed.

**SAFETY DATA SHEET** 

Date of Preparation: 5/7/2021 5130000 Page 3 of 3 **ECOLOGICAL INFORMATION SECTION 12: ECOTOXICITY:** N/E **DEGRADABILITY: N/E BIOACCUMULATIVE POTENTIAL: N/E** OTHER ADVERSE EFFECTS: None Recognized N/E: Not Established **SOIL MOBILITY:** N/E SECTION 13: WASTE DISPOSAL INFORMATION WASTE DISPOSAL INFORMATION: Fuel blending or incineration at a permitted waste disposal facility. SECTION 14: TRANSPORTATION INFORMATION HAZARDOUS/NON-HAZARDOUS MATERIAL: Not regulated by DOT (Domestic Land Transportation). UN NUMBER: None. HAZARD CLASS: N/A **PACKING GROUP: N/A** UN PROPER SHIPPING NAME: N/A ENVIRONMENTAL HAZARDS: None recognized. **BULK TRANSPORTATION INFORMATION: None.** SPECIAL PRECAUTIONS: None. N/A: Not Applicable SECTION 15: REGULATORY INFORMATION OTHER REGULATORY CONSIDERATIONS: None recognized. SECTION 16: OTHER INFORMATION

The information contained herein is based on the data available to us and is believed to be correct. However, we make no warranty, expressed or implied regarding the accuracy of this data or the results to be obtained from the use thereof. We assume no responsibility for injury from the use of this product described herein.

PREPARATION DATE:

PREPARED BY:

5/7/2021

**Dave Carey**